Welcome to our dedicated page for Neurosense Therapeutics news (Ticker: NRSN), a resource for investors and traders seeking the latest updates and insights on Neurosense Therapeutics stock.
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) is a clinical-stage biotechnology company developing novel treatments for severe neurodegenerative diseases, with a primary focus on amyotrophic lateral sclerosis (ALS) and Alzheimer's disease. Its news flow centers on the clinical and regulatory progress of its lead drug candidate, PrimeC, a novel extended-release oral formulation combining two FDA-approved drugs, ciprofloxacin and celecoxib, in a fixed dose designed to target multiple disease mechanisms.
News updates for NRSN commonly cover milestones in ALS and Alzheimer’s clinical programs. These include Phase 2 and Phase 2b trial readouts, such as the PARADIGM study in ALS and the RoAD proof-of-concept study in Alzheimer’s disease, along with biomarker analyses that the company uses to interpret treatment effects. Press releases also highlight safety and tolerability findings, including reports of favorable safety profiles and absence of new or unexpected safety signals in clinical studies.
Investors and observers can expect coverage of regulatory interactions, such as FDA clearance to initiate a pivotal Phase 3 trial of PrimeC in ALS, database lock announcements for Alzheimer’s trials, and updates on planned submissions to agencies like Health Canada. Corporate and financing developments, including private placements of ordinary shares and business updates, are also frequent topics.
This news page aggregates these company-issued announcements, SEC-related communications and other public disclosures about NeuroSense’s progress. It is useful for readers who want to follow NRSN’s clinical trial milestones, biomarker-driven research updates, regulatory steps and capital-raising activities as the company advances PrimeC in ALS and Alzheimer’s disease.
NeuroSense Therapeutics announced positive results from its GLP toxicology study for PrimeC, a combination therapy for ALS. The study confirmed PrimeC's safety at doses over four times the maximal clinical dose, supporting the current Phase IIb PARADIGM trial design. This follows encouraging outcomes from a prior Phase IIa study. The PARADIGM trial aims to assess the efficacy and safety of PrimeC in ALS patients, with topline data expected in H1 2023. This milestone enhances the likelihood of favorable clinical outcomes and supports the drug's development strategy.
NeuroSense Therapeutics announced the peer-reviewed publication of Phase IIa data for its lead drug PrimeC, a combination of ciprofloxacin and celecoxib, targeting ALS. The study demonstrated safety in 15 participants and statistically significant changes in key biomarkers associated with ALS, such as TDP-43 and LC3. Based on promising outcomes, NeuroSense has initiated a Phase IIb clinical trial called PARADIGM. This trial aims to further explore PrimeC's efficacy in ALS treatment by evaluating biomarkers and quality of life improvements.
NeuroSense Therapeutics Ltd. (NRSN) reported its financial results for Q2 2022, highlighting the start of its Phase IIb ALS study and promising biomarker results. The company has over $10 million in cash, supporting its ongoing clinical programs. R&D expenses increased to $3.17 million, while administrative costs rose to $3.69 million, reflecting growth in salaries and professional services. Net loss for the first half of 2022 was $6.2 million, with a basic loss per share of $0.55. The completion of several studies and a key patent were also noted as significant advancements.
NeuroSense Therapeutics (NASDAQ: NRSN) partners with EverythingALS to advance research in developing treatments for Amyotrophic Lateral Sclerosis (ALS). The collaboration includes patient-centric research and financial support for ongoing projects. NeuroSense is also actively enrolling patients in its Phase IIb clinical trial for PrimeC, with top-line results expected in Q2 2023. CEO Alon Ben Noon will present on August 3, 2022, showcasing positive results from earlier studies. The partnership aims to enhance understanding of ALS and improve therapeutic strategies.
NeuroSense Therapeutics (NASDAQ: NRSN) has partnered with NeuraLight to enhance the identification and tracking of digital biomarkers for ALS using AI and machine learning. The collaboration aims to share patient data to improve monitoring of ALS, a severe neurodegenerative disease affecting over 5,000 new patients annually in the U.S. NeuroSense is currently conducting a Phase IIb trial for its lead drug candidate, PrimeC, which has already shown promise in earlier studies.
NeuroSense Therapeutics (Nasdaq: NRSN) provided a corporate update concerning its lead drug candidate, PrimeC, aimed at treating ALS. Two clinical studies launched in Q2 2022, including a Phase IIb trial assessing PrimeC’s efficacy involving 69 ALS patients across Israel, Italy, and the US, with results expected in Q2 2023. A biomarker study indicated PrimeC's potential, while a study on Alzheimer's drug candidate, CogniC, will begin in 2023. The firm focuses on addressing severe neurodegenerative diseases, emphasizing the need for effective therapies.
SpyBiotech has appointed Mark Leuchtenberger as CEO, expanding its leadership team and establishing a U.S. presence with a new office in Cambridge, Massachusetts. Leuchtenberger, with over 20 years in the biopharmaceutical sector, aims to advance the company's proprietary vaccine technology that utilizes SpyTag/SpyCatcher protein superglue. The firm plans to initiate clinical studies for its lead candidate targeting human cytomegalovirus (HCMV) in 2023. The company has raised $39 million to date, including a $32.5 million Series A financing last year.
NeuroSense Therapeutics (NASDAQ: NRSN) announced promising results from its biomarker study for CogniC, a combination drug aimed at treating Alzheimer's disease (AD). The study identified biomarkers indicating CogniC's potential effectiveness in addressing AD pathways, such as miRNA dysregulation and lysosomal dysfunction. High levels of TDP-43 were noted in AD patients, spotlighting its role in the disease. NeuroSense plans to initiate a proof-of-concept clinical trial in 2023, utilizing innovative Neuron-Derived Exosomes technology for biomarker assessment.
NeuroSense Therapeutics (NASDAQ: NRSN) announced encouraging preliminary results from Stage III of its ALS biomarker study, showing that standard care patients had stable disease-related biomarker levels. In contrast, patients treated with PrimeC, NeuroSense's lead drug candidate, demonstrated a significant decline in these biomarkers during the Phase IIa study. The study validates NeuroSense's clinical strategy and aims to optimize a pivotal Phase III study of PrimeC. NeuroSense's approach to ALS treatment is bolstered by collaborations with Massachusetts General Hospital, focusing on innovative biomarkers.
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) will participate in a panel discussion on ALS innovations on June 28, 2022. Co-founder and CEO Alon Ben-Noon will join experts to discuss ALS treatments. The company is currently enrolling participants for its Phase IIb clinical trial, PARADIGM, testing its lead drug candidate, PrimeC, in Israel, Italy, and the USA, with topline results expected in Q2 2023. PrimeC, a combination of ciprofloxacin and celecoxib, received Orphan Drug Designation for targeting ALS. The unmet needs in ALS therapies underscore the significance of this discussion.